{"pmid":32389704,"title":"Pain: A Potential New Label of COVID-19.","text":["Pain: A Potential New Label of COVID-19.","Brain Behav Immun","Su, Si","Cui, Huan","Wang, Tao","Shen, Xinhua","Ma, Chao","32389704"],"journal":"Brain Behav Immun","authors":["Su, Si","Cui, Huan","Wang, Tao","Shen, Xinhua","Ma, Chao"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389704","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.bbi.2020.05.025","keywords":["ace2","covid-19","sars-cov-2","pain"],"topics":["Mechanism"],"weight":1,"_version_":1666528580127948800,"score":9.490897,"similar":[{"pmid":32447087,"title":"Exposure to greenspaces could reduce the high global burden of pain.","text":["Exposure to greenspaces could reduce the high global burden of pain.","Painful conditions are among the leading causes of years lived with disability, and may increase following the coronavirus pandemic, which has led to temporary closure of some healthcare services for people with chronic pain. To reduce this burden, novel, cost-effective and accessible interventions are required. We propose that greenspace exposure may be one such intervention. Drawing on evidence from neuroscience, physiology, microbiology, and psychology, we articulate how and why exposure to greenspaces could improve pain outcomes and reduce the high global burden of pain. Greenspace exposure potentially provides opportunities to benefit from known or proposed health-enhancing components of nature, such as environmental microbiomes, phytoncides, negative air ions, sunlight, and the sights and sounds of nature itself. We review the established and potential links between these specific exposures and pain outcomes. While further research is required to determine possible causal links between greenspace exposure and pain outcomes, we suggest that there is already sufficient evidence to help reduce the global burden of pain by improving access and exposure to quality greenspaces.","Environ Res","Stanhope, Jessica","Breed, Martin F","Weinstein, Philip","32447087"],"abstract":["Painful conditions are among the leading causes of years lived with disability, and may increase following the coronavirus pandemic, which has led to temporary closure of some healthcare services for people with chronic pain. To reduce this burden, novel, cost-effective and accessible interventions are required. We propose that greenspace exposure may be one such intervention. Drawing on evidence from neuroscience, physiology, microbiology, and psychology, we articulate how and why exposure to greenspaces could improve pain outcomes and reduce the high global burden of pain. Greenspace exposure potentially provides opportunities to benefit from known or proposed health-enhancing components of nature, such as environmental microbiomes, phytoncides, negative air ions, sunlight, and the sights and sounds of nature itself. We review the established and potential links between these specific exposures and pain outcomes. While further research is required to determine possible causal links between greenspace exposure and pain outcomes, we suggest that there is already sufficient evidence to help reduce the global burden of pain by improving access and exposure to quality greenspaces."],"journal":"Environ Res","authors":["Stanhope, Jessica","Breed, Martin F","Weinstein, Philip"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447087","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.envres.2020.109641","keywords":["greenspace","microbiome","pain","public health"],"topics":["Prevention"],"weight":1,"_version_":1667698385992286209,"score":65.42813},{"pmid":32389838,"title":"Effects of COVID-19 lockdown on chronic drug-resistant pain patients treated using brain stimulation approach.","text":["Effects of COVID-19 lockdown on chronic drug-resistant pain patients treated using brain stimulation approach.","Brain Stimul","Brocalero-Camacho, Angela","Perez-Borrego, Yolanda A","Soto-Leon, Vanesa","Oliviero, Antonio","Rodriguez-Matas, Maria Jesus","Foffani, Guglielmo","32389838"],"journal":"Brain Stimul","authors":["Brocalero-Camacho, Angela","Perez-Borrego, Yolanda A","Soto-Leon, Vanesa","Oliviero, Antonio","Rodriguez-Matas, Maria Jesus","Foffani, Guglielmo"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389838","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.brs.2020.05.003","keywords":["covid-19","lockdown","motor cortex","pain","transcranial direct current stimulation"],"topics":["Prevention"],"weight":1,"_version_":1666528580227563520,"score":61.259975},{"pmid":32345343,"pmcid":"PMC7186945","title":"COVID-19: ICU delirium management during SARS-CoV-2 pandemic.","text":["COVID-19: ICU delirium management during SARS-CoV-2 pandemic.","The novel coronavirus, SARS-CoV-2-causing Coronavirus Disease 19 (COVID-19), emerged as a public health threat in December 2019 and was declared a pandemic by the World Health Organization in March 2020. Delirium, a dangerous untoward prognostic development, serves as a barometer of systemic injury in critical illness. The early reports of 25% encephalopathy from China are likely a gross underestimation, which we know occurs whenever delirium is not monitored with a valid tool. Indeed, patients with COVID-19 are at accelerated risk for delirium due to at least seven factors including (1) direct central nervous system (CNS) invasion, (2) induction of CNS inflammatory mediators, (3) secondary effect of other organ system failure, (4) effect of sedative strategies, (5) prolonged mechanical ventilation time, (6) immobilization, and (7) other needed but unfortunate environmental factors including social isolation and quarantine without family. Given early insights into the pathobiology of the virus, as well as the emerging interventions utilized to treat the critically ill patients, delirium prevention and management will prove exceedingly challenging, especially in the intensive care unit (ICU). The main focus during the COVID-19 pandemic lies within organizational issues, i.e., lack of ventilators, shortage of personal protection equipment, resource allocation, prioritization of limited mechanical ventilation options, and end-of-life care. However, the standard of care for ICU patients, including delirium management, must remain the highest quality possible with an eye towards long-term survival and minimization of issues related to post-intensive care syndrome (PICS). This article discusses how ICU professionals (e.g., physicians, nurses, physiotherapists, pharmacologists) can use our knowledge and resources to limit the burden of delirium on patients by reducing modifiable risk factors despite the imposed heavy workload and difficult clinical challenges posed by the pandemic.","Crit Care","Kotfis, Katarzyna","Williams Roberson, Shawniqua","Wilson, Jo Ellen","Dabrowski, Wojciech","Pun, Brenda T","Ely, E Wesley","32345343"],"abstract":["The novel coronavirus, SARS-CoV-2-causing Coronavirus Disease 19 (COVID-19), emerged as a public health threat in December 2019 and was declared a pandemic by the World Health Organization in March 2020. Delirium, a dangerous untoward prognostic development, serves as a barometer of systemic injury in critical illness. The early reports of 25% encephalopathy from China are likely a gross underestimation, which we know occurs whenever delirium is not monitored with a valid tool. Indeed, patients with COVID-19 are at accelerated risk for delirium due to at least seven factors including (1) direct central nervous system (CNS) invasion, (2) induction of CNS inflammatory mediators, (3) secondary effect of other organ system failure, (4) effect of sedative strategies, (5) prolonged mechanical ventilation time, (6) immobilization, and (7) other needed but unfortunate environmental factors including social isolation and quarantine without family. Given early insights into the pathobiology of the virus, as well as the emerging interventions utilized to treat the critically ill patients, delirium prevention and management will prove exceedingly challenging, especially in the intensive care unit (ICU). The main focus during the COVID-19 pandemic lies within organizational issues, i.e., lack of ventilators, shortage of personal protection equipment, resource allocation, prioritization of limited mechanical ventilation options, and end-of-life care. However, the standard of care for ICU patients, including delirium management, must remain the highest quality possible with an eye towards long-term survival and minimization of issues related to post-intensive care syndrome (PICS). This article discusses how ICU professionals (e.g., physicians, nurses, physiotherapists, pharmacologists) can use our knowledge and resources to limit the burden of delirium on patients by reducing modifiable risk factors despite the imposed heavy workload and difficult clinical challenges posed by the pandemic."],"journal":"Crit Care","authors":["Kotfis, Katarzyna","Williams Roberson, Shawniqua","Wilson, Jo Ellen","Dabrowski, Wojciech","Pun, Brenda T","Ely, E Wesley"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32345343","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1186/s13054-020-02882-x","keywords":["covid-19","delirium","pics","ptsd","pain","pandemic","sars-cov-2","sedation"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1666138494970363904,"score":45.468483},{"pmid":32419438,"title":"COVID-19: What do we need to know about ICU delirium during the SARS-CoV-2 pandemic?","text":["COVID-19: What do we need to know about ICU delirium during the SARS-CoV-2 pandemic?","In March 2020, the World Health Organisation announced the COVID-19 pandemic caused by the SARS-CoV-2 virus. As well as respiratory failure, the SARS-CoV-2 may cause central nervous system (CNS) involvement, including delirium occurring in critically ill patients (ICU delirium). Due attention must be paid to this subject in the face of the COVID-19 pandemic. Delirium, the detection of which takes less than two minutes, is frequently underestimated during daily routine ICU care, but it may be a prodromal symptom of infection or hypoxia associated with severe respiratory failure. During the COVID-19 pandemic, systematic delirium monitoring using validated tests (CAM-ICU or ICDSC) may be sacrificed. This is likely to be due to the fact that the main emphasis is placed on organisational issues, i.e. the lack of ventilators, setting priorities for limited mechanical ventilation options, and a shortage of personal protective equipment. Early identification of patients with delirium is critical in patients with COVID-19 because the occurrence of delirium may be an early symptom of worsening respiratory failure or of infectious spread to the CNS mediated by potential neuroinvasive mechanisms of the coronavirus. The purpose of this review is to identify problems related to the development of delirium during the COVID-19 epidemic, which are presented in three areas: i) factors contributing to delirium in COVID-19, ii) potential pathophysiological factors of delirium in COVID-19, and iii) long-term consequences of delirium in COVID-19. This article discusses how healthcare workers can reduce the burden of delirium by identifying potential risk factors and difficulties during challenges associated with SARS-CoV-2 infection.","Anaesthesiol Intensive Ther","Kotfis, Katarzyna","Williams Roberson, Shawniqua","Wilson, Jo","Pun, Brenda","Ely, E Wesley","Jezowska, Ilona","Jezierska, Maja","Dabrowski, Wojciech","32419438"],"abstract":["In March 2020, the World Health Organisation announced the COVID-19 pandemic caused by the SARS-CoV-2 virus. As well as respiratory failure, the SARS-CoV-2 may cause central nervous system (CNS) involvement, including delirium occurring in critically ill patients (ICU delirium). Due attention must be paid to this subject in the face of the COVID-19 pandemic. Delirium, the detection of which takes less than two minutes, is frequently underestimated during daily routine ICU care, but it may be a prodromal symptom of infection or hypoxia associated with severe respiratory failure. During the COVID-19 pandemic, systematic delirium monitoring using validated tests (CAM-ICU or ICDSC) may be sacrificed. This is likely to be due to the fact that the main emphasis is placed on organisational issues, i.e. the lack of ventilators, setting priorities for limited mechanical ventilation options, and a shortage of personal protective equipment. Early identification of patients with delirium is critical in patients with COVID-19 because the occurrence of delirium may be an early symptom of worsening respiratory failure or of infectious spread to the CNS mediated by potential neuroinvasive mechanisms of the coronavirus. The purpose of this review is to identify problems related to the development of delirium during the COVID-19 epidemic, which are presented in three areas: i) factors contributing to delirium in COVID-19, ii) potential pathophysiological factors of delirium in COVID-19, and iii) long-term consequences of delirium in COVID-19. This article discusses how healthcare workers can reduce the burden of delirium by identifying potential risk factors and difficulties during challenges associated with SARS-CoV-2 infection."],"journal":"Anaesthesiol Intensive Ther","authors":["Kotfis, Katarzyna","Williams Roberson, Shawniqua","Wilson, Jo","Pun, Brenda","Ely, E Wesley","Jezowska, Ilona","Jezierska, Maja","Dabrowski, Wojciech"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419438","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.5114/ait.2020.95164","keywords":["pics","ptsd","sars-cov-2","coronavirus","delirium","pain","pandemic","sedation","covid-19"],"locations":["hypoxia"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667254896656646144,"score":45.468483},{"pmid":32227090,"pmcid":"PMC7184507","title":"The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2.","text":["The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2.","A new type of pneumonia caused by a novel coronavirus SARS-CoV-2 outbreaks recently in China and spreads into many other countries. This disease, named as COVID-19, is similar to patients infected by SARS-CoV and MERS-CoV, and nearly 20% of patients developed severe condition. Cardiac injury is a prevalent complication of severe patients, exacerbating the disease severity in coronavirus disease 2019 (COVID-19) patients. Angiotensin-converting enzyme 2 (ACE2), the key host cellular receptor of SARS-CoV-2, has been identified in multiple organs, but its cellular distribution in human heart is not illuminated clearly. This study performed the first state-of-art single cell atlas of adult human heart, and revealed that pericytes with high expression of ACE2 might act as the target cardiac cell of SARS-CoV-2. The pericytes injury due to virus infection may result in capillary endothelial cells dysfunction, inducing microvascular dysfunction. And patients with basic heart failure disease showed increased ACE2 expression at both mRNA and protein levels, meaning that if infected by the virus these patients may have higher risk of heart attack and critically ill condition. The finding of this study explains the high rate of severe cases among COVID-19 patients with basic cardiovascular disease; and these results also perhaps provide important reference to clinical treatment of cardiac injury among severe patients infected by SARS-CoV-2.","Cardiovasc Res","Chen, Liang","Li, Xiangjie","Chen, Mingquan","Feng, Yi","Xiong, Chenglong","32227090"],"abstract":["A new type of pneumonia caused by a novel coronavirus SARS-CoV-2 outbreaks recently in China and spreads into many other countries. This disease, named as COVID-19, is similar to patients infected by SARS-CoV and MERS-CoV, and nearly 20% of patients developed severe condition. Cardiac injury is a prevalent complication of severe patients, exacerbating the disease severity in coronavirus disease 2019 (COVID-19) patients. Angiotensin-converting enzyme 2 (ACE2), the key host cellular receptor of SARS-CoV-2, has been identified in multiple organs, but its cellular distribution in human heart is not illuminated clearly. This study performed the first state-of-art single cell atlas of adult human heart, and revealed that pericytes with high expression of ACE2 might act as the target cardiac cell of SARS-CoV-2. The pericytes injury due to virus infection may result in capillary endothelial cells dysfunction, inducing microvascular dysfunction. And patients with basic heart failure disease showed increased ACE2 expression at both mRNA and protein levels, meaning that if infected by the virus these patients may have higher risk of heart attack and critically ill condition. The finding of this study explains the high rate of severe cases among COVID-19 patients with basic cardiovascular disease; and these results also perhaps provide important reference to clinical treatment of cardiac injury among severe patients infected by SARS-CoV-2."],"journal":"Cardiovasc Res","authors":["Chen, Liang","Li, Xiangjie","Chen, Mingquan","Feng, Yi","Xiong, Chenglong"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32227090","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1093/cvr/cvaa078","keywords":["ace2","heart failure","heart injury","sars-cov-2"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138492433858560,"score":44.252804}]}